The US Food and Drug Administration (FDA) has expanded the use of Casgevy (exagamglogene autotemcel) for the treatment of people ages two years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT).   The approval makes Casgevy the first approved genetic therapy indicated for children as young […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!